Earlier, December 2020: Both Pfizer And Moderna Could Have Announced Their Vaccines' Efficacy Before The Election, Which Likely Would Have Meant A Trump Victory

From my new column in Taki’s Magazine:

The Missing Piece
Steve Sailer

March 23, 2022

Dr. Albert Bourla, CEO of pharmaceutical giant Pfizer, has published a new memoir entitled Moonshot: Inside Pfizer’s Nine-Month Race to Make the Impossible Possible.

While the revolutionary mRNA vaccine from Pfizer-BioNTech has not turned out to be as much of a panacea as hoped, for people at risk (e.g., older and/or fatter, like most of us) it remains effective at reducing the odds of dying or being ventilated due to Covid. A new CDC report finds that two doses eight months ago were 79 percent efficacious against the recent Omicron variant. Add a booster shot and efficacy is back up to an impressive 94 percent.

I read Bourla’s Moonshot carefully in the hope of finally hearing a horse’s-mouth explanation of his curious decision in what he calls “the most important trial in the world” to shut down laboratory processing of samples from late October 2020 until the day after the election. This extraordinary freeze may well have denied Donald Trump his much-feared “October Surprise” upon which his vaccine-centric pandemic and reelection strategies hinged.

Read the whole thing there.

[Comment at Unz.com]